Log in

NASDAQ:VYGRVoyager Therapeutics Stock Price, Forecast & News

$11.19
+0.20 (+1.82 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.79
Now: $11.19
$11.34
50-Day Range
$10.35
MA: $12.64
$14.21
52-Week Range
$6.26
Now: $11.19
$23.50
Volume212,092 shs
Average Volume309,359 shs
Market Capitalization$416.16 million
P/E RatioN/A
Dividend YieldN/A
Beta1.82
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD101 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreements with AbbVie Inc.; Sanofi Genzyme; the University of Massachusetts; and MRI Interventions, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
Voyager Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VYGR
CUSIPN/A
Phone857-259-5340

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$104.39 million
Book Value$2.68 per share

Profitability

Net Income$-43,600,000.00

Miscellaneous

Employees123
Market Cap$416.16 million
Next Earnings Date8/10/2020 (Confirmed)
OptionableOptionable
$11.19
+0.20 (+1.82 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VYGR News and Ratings via Email

Sign-up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions

How has Voyager Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Voyager Therapeutics' stock was trading at $9.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VYGR shares have increased by 18.7% and is now trading at $11.19.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Voyager Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Voyager Therapeutics
.

When is Voyager Therapeutics' next earnings date?

Voyager Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Voyager Therapeutics
.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics Inc (NASDAQ:VYGR) released its earnings results on Wednesday, May, 6th. The company reported ($0.66) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.79) by $0.13. The business earned $18.07 million during the quarter, compared to analyst estimates of $8.70 million. Voyager Therapeutics had a negative net margin of 34.70% and a negative return on equity of 40.11%.
View Voyager Therapeutics' earnings history
.

What price target have analysts set for VYGR?

10 Wall Street analysts have issued 12 month target prices for Voyager Therapeutics' shares. Their forecasts range from $13.00 to $27.00. On average, they anticipate Voyager Therapeutics' share price to reach $18.11 in the next year. This suggests a possible upside of 61.9% from the stock's current price.
View analysts' price targets for Voyager Therapeutics
.

What are Wall Street analysts saying about Voyager Therapeutics stock?

Here are some recent quotes from research analysts about Voyager Therapeutics stock:
  • 1. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (5/9/2020)
  • 2. Nomura Securities analysts commented, "Minor Tweaks Post-NBIX Collab., Revising Patient Numbers and Statistical Plan; No Data Guidance Yet. The first pivotal Parkinson’s disease trial, RESTORE-1, is undergoing minor modifications now that VYGR is partnered with NBIX. VYGR had previously guided to a 75-100 patient trial, but this is likely going to be clarified as the statistical analysis plan is finalized. No data guidance yet—but we expect an update when the target enrollment is finalized and when VYGR gets a sense of the pace of enrollment. Huntington’s Program IND by YE19 – Finalizing Clinical Team and Planning to Use Commercial-Grade Gene Therapy Material. Voyager recently attained full rights after the SNY collaboration restructuring (see our note here). VYGR plans to have an IND by YE19 and will use material that is “very, very similar” to commercial material to avoid any step back in the future." (8/13/2019)
  • 3. HC Wainwright analysts commented, "Our current target is based on a 12-year DCF analysis primarily focused on VY-AADC in PD. Our DCF analysis is based on: beta of 1.62, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2030." (8/12/2019)

Has Voyager Therapeutics been receiving favorable news coverage?

News articles about VYGR stock have been trending extremely negative on Sunday, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Voyager Therapeutics earned a news sentiment score of -4.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Voyager Therapeutics
.

Are investors shorting Voyager Therapeutics?

Voyager Therapeutics saw a decline in short interest in the month of July. As of July 31st, there was short interest totaling 2,780,000 shares, a decline of 11.5% from the July 15th total of 3,140,000 shares. Based on an average trading volume of 322,300 shares, the days-to-cover ratio is currently 8.6 days. Approximately 11.6% of the company's stock are sold short.
View Voyager Therapeutics' Short Interest
.

Who are some of Voyager Therapeutics' key competitors?

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), Crispr Therapeutics (CRSP), Regenxbio (RGNX), TG Therapeutics (TGTX), NVIDIA (NVDA), AbbVie (ABBV), Editas Medicine (EDIT), ImmunoGen (IMGN), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the following people:
  • Mr. Matthew P. Ottmer, Chief Operating Officer (Age 48)
  • Dr. Steven M. Paul, Exec. Science Advisor & Director (Age 68)
  • Mr. G. Andre Turenne, CEO, Pres & Director
  • Dr. Krystof Bankiewicz M.D., Ph.D., Founder
  • Dr. Guangping Gao Ph.D., Founder

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Raymond James Financial Services Advisors Inc. (0.55%), Russell Investments Group Ltd. (0.18%), Hancock Whitney Corp (0.17%), Alps Advisors Inc. (0.14%), Strs Ohio (0.10%) and Trexquant Investment LP (0.08%). Company insiders that own Voyager Therapeutics stock include Allison Dorval, Andre Turenne, Glenn Pierce, James A Geraghty, Matthew P Ottmer, Neurocrine Biosciences Inc, Omar Khwaja and Robert W Hesslein.
View institutional ownership trends for Voyager Therapeutics
.

Which major investors are selling Voyager Therapeutics stock?

VYGR stock was sold by a variety of institutional investors in the last quarter, including Trexquant Investment LP, Alps Advisors Inc., Hancock Whitney Corp, Russell Investments Group Ltd., and Strs Ohio. Company insiders that have sold Voyager Therapeutics company stock in the last year include Allison Dorval, Andre Turenne, Matthew P Ottmer, Omar Khwaja, and Robert W Hesslein.
View insider buying and selling activity for Voyager Therapeutics
.

Which major investors are buying Voyager Therapeutics stock?

VYGR stock was bought by a variety of institutional investors in the last quarter, including Rafferty Asset Management LLC, Cornerstone Investment Partners LLC, Raymond James Financial Services Advisors Inc., New York State Common Retirement Fund, UBS Group AG, SG Americas Securities LLC, Virtus ETF Advisers LLC, and Patriot Financial Group Insurance Agency LLC. Company insiders that have bought Voyager Therapeutics stock in the last two years include Glenn Pierce, James A Geraghty, and Neurocrine Biosciences Inc.
View insider buying and selling activity for Voyager Therapeutics
.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $11.19.

How big of a company is Voyager Therapeutics?

Voyager Therapeutics has a market capitalization of $416.16 million and generates $104.39 million in revenue each year. The company earns $-43,600,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Voyager Therapeutics employs 123 workers across the globe.

What is Voyager Therapeutics' official website?

The official website for Voyager Therapeutics is www.voyagertherapeutics.com.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-5340 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.